Alzamend Neuro Inc (ALZN)
$1.35+3.05%Close
SELLCRISIS · day 9
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4M
- Beta
- 0.19
- P/E (TTM)
- -0.59
- Short % float
- 3.67%
- Days to cover
- 1.1
- SI change
- -9.3%
- 1W
- -1.46%
- 1M
- -22.86%
- vs SPY 1W
- -1.32%
- vs SPY 1M
- -25.36%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 6
- GROWTH
- 40
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-166.7%
REV YoY-
ROE-391.4%
EPS YoY-
ROA-106.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.59
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.04
P/FCF-
EV/EBITDA0.27
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO3.01
ND/EBITDA-
BETA0.19
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on ALZN?
- LOPJLB’s latest quantitative signal on Alzamend Neuro Inc (ALZN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ALZN in?
- Alzamend Neuro Inc (ALZN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Alzamend Neuro Inc (ALZN) do?
- Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other ne…